Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -74.58% is 42% below its 5-year average of -52.44%, near the low end of its 5-year range (-89.80%–-17.42%).
6.97% below its 12-month average of -69.72%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -60.88%.
RETURN ON ASSETS (ROA)
-74.58%
RETURN ON ASSETS (ROA) AVG TTM
-69.72%
RETURN ON ASSETS (ROA) AVG 3Y
-51.64%
RETURN ON ASSETS (ROA) AVG 5Y
-52.44%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-6.97%
CURRENT VS 3Y AVG
-44.41%
CURRENT VS 5Y AVG
-42.22%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-131.33%
vs the sector median at left
Quince Therapeutics, Inc.
Market Cap
$7.64M
Return on Assets (ROA)
-74.58%
TTM Avg
-69.72%
3Y Avg
-51.64%
5Y Avg
-52.44%
Market Cap
$7.75M
Return on Assets (ROA)
-76.12%
TTM Avg
-177.28%
3Y Avg
-394.98%
5Y Avg
-300.85%
Market Cap
$7.86M
Return on Assets (ROA)
-74.50%
TTM Avg
-220.41%
3Y Avg
-182.97%
5Y Avg
-158.82%
Market Cap
$7.93M
Return on Assets (ROA)
86.37%
TTM Avg
-66.33%
3Y Avg
-66.09%
5Y Avg
-69.89%
Market Cap
$7.86M
Return on Assets (ROA)
-29.10%
TTM Avg
-66.56%
3Y Avg
-142.45%
5Y Avg
-115.37%
Market Cap
$8.08M
Return on Assets (ROA)
-381.53%
TTM Avg
-330.40%
3Y Avg
-209.86%
5Y Avg
-253.27%
Market Cap
$7.29M
Return on Assets (ROA)
-457.62%
TTM Avg
-117.02%
3Y Avg
-190.78%
5Y Avg
-182.53%
Market Cap
$7.25M
Return on Assets (ROA)
-414.54%
TTM Avg
-226.50%
3Y Avg
-135.75%
5Y Avg
-126.75%
Market Cap
$7.21M
Return on Assets (ROA)
-151.57%
TTM Avg
-141.88%
3Y Avg
-132.44%
5Y Avg
-101.65%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | $7.64M | -74.58% | -69.72% | -51.64% | -52.44% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.75M | -76.12% | -177.28% | -394.98% | -300.85% |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.86M | -74.50% | -220.41% | -182.97% | -158.82% |
| Traws Pharma, Inc. (TRAW)vs › | $7.93M | 86.37% | -66.33% | -66.09% | -69.89% |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.86M | -29.10% | -66.56% | -142.45% | -115.37% |
| GT Biopharma, Inc. (GTBP)vs › | $8.08M | -381.53% | -330.40% | -209.86% | -253.27% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.29M | -457.62% | -117.02% | -190.78% | -182.53% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.25M | -414.54% | -226.50% | -135.75% | -126.75% |
| Longeveron Inc. (LGVN)vs › | $7.21M | -151.57% | -141.88% | -132.44% | -101.65% |
| HeartSciences Inc. (HSCS)vs › | $8.26M | N/A | -103.86% | -117.64% | -138.14% |
ROA
-74.6%
ROE
-85.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -89.80% |
| 2024-12-31 | -49.64% |
| 2023-12-31 | -17.42% |
| 2022-12-31 | -49.72% |
| 2021-12-31 | -67.51% |
| 2020-12-31 | -40.56% |
| 2019-12-31 | -29.73% |
| 2018-12-31 | -17.12% |
| 2017-12-31 | -158.53% |
